Literature DB >> 16850145

Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection.

Etsuro Hatano1, Iwao Ikai, Tatsuya Higashi, Satoshi Teramukai, Tatsuo Torizuka, Tsuneo Saga, Hideaki Fujii, Yasuyuki Shimahara.   

Abstract

BACKGROUND: Hepatocellular carcinomas (HCCs) accumulate fluorine-18 fluorodeoxyglucose (FDG) to various degrees. The standardized uptake values (SUVs) of FDG-positron emission tomography (PET) in high-grade HCCs are significantly higher than those in low-grade HCCs. AIM: The aim of this study was to evaluate the possible usefulness of FDG-PET in predicting the prognosis of HCC patients after resection. We analyzed the relationship between the tumor to non-tumor SUV ratios (SUV ratio) and surgical outcome in 31 patients.
RESULTS: Of the 31 cases of HCC studied, seven (23%) exhibited SUV ratios greater than 2, as the cutoff value. The percentage of patients with poorly differentiated HCC was greater in the higher SUV ratio group (SUV ratio >2) than in the lower SUV ratio group (SUV ratio <2) (57 vs. 32%). The overall survival was significantly longer in the lower SUV ratio group than in the higher SUV ratio group (5-year-survival rate: 63 vs. 29% P = 0.006) (median survival time: 2310 vs.182 days).
CONCLUSION: The SUV ratio was related significantly to disease-related death as well as other predictive factors, including the number of tumors, the size, stage, and involvement of vessels, and the involvement of the capsule. Consequently, we conclude that the SUV ratio provides information of prognostic relevance in patients with HCC before surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16850145     DOI: 10.1007/s00268-005-0791-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  23 in total

1.  [Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma].

Authors:  Yun Ho Kong; Chul Ju Han; Sang Dae Lee; Wee Sik Sohn; Min Jae Kim; Seung Seog Ki; Jin Kim; Sook Hyang Jeong; You Cheoul Kim; Jhin Oh Lee; Gi Jeong Cheon; Chang Woon Choi; Sang Moo Lim
Journal:  Korean J Hepatol       Date:  2004-12

2.  Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma.

Authors:  S Shiomi; S Nishiguchi; H Ishizu; Y Iwata; N Sasaki; A Tamori; D Habu; T Takeda; S Kubo; H Ochi
Journal:  Am J Gastroenterol       Date:  2001-06       Impact factor: 10.864

3.  The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.

Authors:  V Ahuja; R E Coleman; J Herndon; E F Patz
Journal:  Cancer       Date:  1998-09-01       Impact factor: 6.860

4.  Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation.

Authors:  S Tamura; T Kato; M Berho; E P Misiakos; C O'Brien; K R Reddy; J R Nery; G W Burke; E R Schiff; J Miller; A G Tzakis
Journal:  Arch Surg       Date:  2001-01

Review 5.  Whole-body FDG-PET imaging in the management of patients with cancer.

Authors:  Roland Hustinx; François Bénard; Abass Alavi
Journal:  Semin Nucl Med       Date:  2002-01       Impact factor: 4.446

6.  The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.

Authors:  L James Wudel; Dominique Delbeke; David Morris; Michael Rice; Mary Kay Washington; Yu Shyr; C Wright Pinson; William C Chapman
Journal:  Am Surg       Date:  2003-02       Impact factor: 0.688

7.  Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey.

Authors:  Iwao Ikai; Shigeki Arii; Masamichi Kojiro; Takafumi Ichida; Masatoshi Makuuchi; Yutaka Matsuyama; Yasuni Nakanuma; Kiwamu Okita; Masao Omata; Kenichi Takayasu; Yoshio Yamaoka
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860

8.  Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers.

Authors:  Long-Bin Jeng; Sheng-Pin Changlai; Yeh-You Shen; Cheng-Chieh Lin; Chang-Hai Tsai; Chia-Hung Kao
Journal:  Hepatogastroenterology       Date:  2003 Nov-Dec

9.  In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.

Authors:  T Torizuka; N Tamaki; T Inokuma; Y Magata; S Sasayama; Y Yonekura; A Tanaka; Y Yamaoka; K Yamamoto; J Konishi
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

10.  18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma.

Authors:  Masahiro Sugiyama; Harumi Sakahara; Tatsuo Torizuka; Toshihiko Kanno; Fumitoshi Nakamura; Masami Futatsubashi; Satoshi Nakamura
Journal:  J Gastroenterol       Date:  2004-10       Impact factor: 7.527

View more
  30 in total

1.  Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients.

Authors:  Nobuyuki Hayakawa; Yuji Nakamoto; Koya Nakatani; Etsuro Hatano; Satoru Seo; Tatsuya Higashi; Tsuneo Saga; Shinji Uemoto; Kaori Togashi
Journal:  Int J Clin Oncol       Date:  2013-12-25       Impact factor: 3.402

Review 2.  Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

Authors:  Yu-Yun Shao; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

3.  Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria.

Authors:  Seung Duk Lee; Bora Lee; Seong Hoon Kim; Jungnam Joo; Seok-Ki Kim; Young-Kyu Kim; Sang-Jae Park
Journal:  World J Transplant       Date:  2016-06-24

Review 4.  Liver transplantation for advanced hepatocellular carcinoma: how far can we go?

Authors:  Kyung-Suk Suh; Hae Won Lee
Journal:  Hepat Oncol       Date:  2015-01-12

5.  FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations.

Authors:  Koji Murakami
Journal:  World J Clin Oncol       Date:  2011-05-10

Review 6.  Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review.

Authors:  Dong-Wei Xu; Ping Wan; Qiang Xia
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

7.  Positron emission tomography/computer tomography in guidance of extrahepatic hepatocellular carcinoma metastasis management.

Authors:  Long Sun; Yong-Song Guan; Wei-Ming Pan; Gui-Bing Chen; Zuo-Ming Luo; Hua Wu
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

8.  Comparison of uptake characteristics and prognostic value of 201Tl and 18F-FDG in esophageal cancer.

Authors:  Hyun Woo Chung; Kyung-Han Lee; Eun Jeong Lee; Su Jin Lee; Young Seok Cho; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Byung-Tae Kim
Journal:  World J Surg       Date:  2008-01       Impact factor: 3.352

9.  Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.

Authors:  Daiki Yamashige; Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Satoshi Okubo; Nozomu Muraishi; Akira Kajiwara; Soichi Iritani; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Oncology       Date:  2020-11-18       Impact factor: 2.935

10.  FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma.

Authors:  Tatsuya Higashi; Etsuro Hatano; Iwao Ikai; Ryuichi Nishii; Yuji Nakamoto; Koichi Ishizu; Tsuyoshi Suga; Hidekazu Kawashima; Kaori Togashi; Satoru Seo; Koji Kitamura; Yasutsugu Takada; Yasuji Takada; Shinji Uemoto; Shinji Kamimoto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.